U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07108283) titled 'A Study of Zasocitinib in Adults With Nonsegmental Vitiligo' on Aug. 05.
Brief Summary: Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches).
The main aim of this study is to learn how safe zasocitinib is, ...